Dynavax Technologies reported $220.22M in Debt for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Adma Biologics ADMA:US $ 94.36M 0.49M
Alexion Pharmaceuticals ALXN:US $ 2532M 30M
Amgen AMGN:US $ 37579M 4797M
Astrazeneca AZN:US $ 31912M 4417M
AstraZeneca AZN:LN 31912M 4417M
Biogen BIIB:US $ 7271.1M 1.9M
Biomarin Pharmaceutical BMRN:US $ 1078.09M 0.98M
Bristol Myers Squibb BMY:US $ 44742M 416M
Chimerix CMRX:US $ 14M 0M
Dynavax Technologies DVAX:US $ 220.22M 0.26M
Glaxosmithkline GSK:US $ 25605M 122M
Gw Pharmaceuticals GWPH:US $ 15.19M 0.11M
Idera Pharmaceuticals IDRA:US $ 0M 0M
Minerva Neurosciences NERV:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 330.7M 4.4M
Novartis NOVN:VX SF 34243M 1526M
Regeneron Pharmaceuticals REGN:US $ 2698.6M 1M
Sarepta Therapeutics SRPT:US $ 1094.91M 1.93M
Vertex Pharmaceuticals VRTX:US $ 513.26M 11.67M